F-1: RedHill Biopharma Secures $10 Million Equity Line Amidst Nasdaq Compliance Woes and Ongoing Litigation

RedHill Biopharma Ltd. has filed an F-1 registration statement for the resale of up to 5.6 million American Depositary Shares by Alumni Capital LP, stemming from a new $10 million equity line of credit, as the company grapples with a significant stockholders' deficit and Nasdaq listing non-compliance.

Summary

• RedHill Biopharma Ltd. has filed an F-1 registration statement for the resale of up to 5,596,490 American Depositary Shares (ADSs) by Alumni Capital LP, which includes 5,263,157 ADSs from a new $10 million committed equity line of credit and 333,333 ADSs from a commitment warrant.
• The company will not receive direct proceeds from the resale of these ADSs by the selling shareholder, but will receive exercise prices from any exercised warrants for general corporate purposes.
• As of December 31, 2024, RedHill reported a stockholders' deficit of $4,683,000, falling short of Nasdaq's minimum stockholders' equity requirement of $2,500,000, leading to a notification of non-compliance on April 15, 2025.
• RedHill was awarded an approximately $8 million judgment (including $6.5 million principal and ~$1.5 million accrued interest as of December 2, 2024) in its lawsuit against Kukbo Co. Ltd., with all counterclaims dismissed; however, Kukbo has appealed the decision.
• In February 2025, RedHill entered an exclusive worldwide licensing agreement (excluding North America) with Hyloris Pharmaceuticals SA for RHB-102 (Bekinda), which includes an upfront payment, up to $60 million in potential milestone payments, and up to mid-20s percent royalties on revenues.
• The company previously sold 890,001 ADSs for approximately $3.3 million in net proceeds at a weighted average price of $3.85 per ADS through an At-The-Market (ATM) program with H.C. Wainwright & Co., LLC.
• RedHill's Articles of Association were amended on May 26, 2025, to increase authorized share capital to NIS 1,600,000,000, and its Compensation Policy was also amended on the same date.

Sentiment

Score: 3

Explanation: While the company has secured a new equity line of credit and won a significant legal judgment, its substantial stockholders' deficit and ongoing Nasdaq non-compliance indicate significant financial distress. The capital raise appears to be a necessary measure to address liquidity and compliance issues rather than a sign of strong growth or positive operational performance, and the legal victory is still subject to appeal.

Positives

• Secured a new $10 million equity line of credit with Alumni Capital LP, providing a potential source of capital.
• Awarded an approximately $8 million judgment in the Kukbo litigation, with all counterclaims dismissed, representing a significant legal victory.
• Entered into a licensing agreement with Hyloris Pharmaceuticals for RHB-102, which includes an upfront payment and potential milestone payments up to $60 million plus royalties, indicating progress in commercialization strategy.
• Successfully raised approximately $3.3 million in net proceeds through an At-The-Market (ATM) program, demonstrating recent access to capital markets.

Negatives

• Reported a significant stockholders' deficit of $4,683,000 as of December 31, 2024, indicating a challenging financial position.
• Received a Nasdaq notification of non-compliance with the minimum stockholders' equity rule, posing a risk of delisting.
• The company's financial statements include a 'going concern' reference, highlighting substantial doubt about its ability to continue operations without additional financing.
• The $10 million equity line of credit does not guarantee the full amount will be raised due to fluctuating market prices and beneficial ownership limitations.
• The $8 million judgment in the Kukbo litigation is under appeal, creating uncertainty regarding the timing and ultimate collection of funds and potential for continued legal costs.
• Operations in Israel face risks due to the ongoing political and security situation, which could disrupt business, affect labor availability, and impact supply chains.

Risks

• The company's ability to continue operations is dependent on obtaining additional financing or successfully concluding a strategic business transaction, as indicated by a 'going concern' reference in its financial statements.
• Failure to regain and maintain compliance with Nasdaq's continued listing requirements, including the minimum stockholders' equity of $2.5 million and minimum bid price, could result in the delisting of ADSs.
• The actual number of shares sold under the $10 million equity line of credit and the gross proceeds received are unpredictable due to fluctuating market prices and beneficial ownership limitations (4.99% of outstanding ADSs or share capital) for the selling shareholder.
• Future sales and issuances of ADSs or other securities, particularly under the equity line of credit, could result in significant dilution to existing shareholders and depress the market price of ADSs.
• The ongoing lawsuit against Kukbo Co. Ltd., despite a favorable judgment, carries risks of not prevailing on appeal or being unable to collect the awarded amounts, potentially incurring further legal fees and diverting management attention.
• The company's operations in Israel are exposed to economic, political, geopolitical, and military conditions, including ongoing conflicts and regional instability, which could adversely affect business, supply chains, and ability to raise capital.
• There is no assurance that the company will not be characterized as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for 2025, which could lead to adverse tax consequences for U.S. holders of ADSs.
• Reliance on third parties for key commercial operations, clinical trials, manufacturing, and supply chain functions poses risks if these parties do not perform satisfactorily.
• The company's ability to establish and maintain intellectual property rights and operate its business without infringing on the intellectual property rights of others is a continuous risk.
• There is a risk that parties from whom the company licenses or acquires intellectual property, or its partners, may default on their obligations.

Future Outlook

RedHill Biopharma aims to become a leading specialty biopharmaceutical company, primarily focused on advancing its clinical-stage therapeutic candidates in GI, infectious diseases, and oncology. The company plans to commercialize its therapeutic candidates, upon approval, through licensing and other commercialization arrangements or independently. It intends to continue the development for FDA approval of RHB-102 in the U.S. The company is also exploring opaganib and RHB-107 for various conditions, including viral infections as part of pandemic preparedness.

Management Comments

• "We intend to vigorously pursue the recovery of attorneys fees and the collection of the judgment" regarding the Kukbo litigation.
• "We are looking into various options available to regain compliance and maintain our continued listing on The Nasdaq Capital Market."

Industry Context

RedHill Biopharma operates in the specialty biopharmaceutical sector, with a focus on gastrointestinal (GI), infectious diseases, and oncology. The company's strategy involves both internal development (e.g., Talicia) and in-licensing/acquiring products to build its pipeline. Its approach to commercialization includes out-licensing for specific territories and evaluating co-development, co-promotion, and acquisition arrangements. The mention of opaganib and RHB-107 for viral infections and pandemic preparedness aligns with broader industry trends emphasizing readiness for global health threats.

Corporate Governance

Legal Proceedings

• RedHill filed a lawsuit against Kukbo Co. Ltd. on September 2, 2022, for default on a $5.0 million subscription agreement and a $1.5 million payment under an Exclusive License Agreement.
• Kukbo filed counterclaims alleging breach of contract, misrepresentation, and breach of duty of good faith and fair dealing.
• On December 2, 2024, RedHill was awarded a summary judgment of approximately $8 million (including $6.5 million principal and ~$1.5 million accrued interest) by the Supreme Court of the State of New York, which also dismissed all of Kukbo's counterclaims.
• Kukbo filed a notice of appeal and perfected its appeal on June 4, 2025.
• RedHill intends to file its response to Kukbo's appeal on or before August 6, 2025.
• The appeal is currently set for hearing in the Supreme Court of the State of New York, Appellate Division, First Judicial Department's September 2025 term.
• RedHill has a contingency fee agreement with its legal firm, Haynes and Boone, LLP, for the litigation, under which the firm is entitled to a double-digit percentage of any gross recovery if the case ends in a final favorable outcome not subject to further appeal.

Related Party Transactions

• The Any Market Purchase Agreement, dated June 20, 2025, between RedHill Biopharma Ltd. and Alumni Capital LP, establishes a $10 million committed equity line of credit. Alumni Capital LP is identified as the Selling Shareholder in this prospectus and is deemed an underwriter under the Securities Act.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the equity line of credit sales, risk of delisting from Nasdaq due to non-compliance, and uncertainty regarding the ultimate collection of the Kukbo judgment. The Israeli geopolitical situation also poses risks to investment value.
• **Employees**: Potential for disruptions to daily tasks and labor availability due to military reserve duty call-ups and security measures in Israel.
• **Customers/Suppliers**: Possible disruptions to supply chains due to regional conflicts (e.g., Red Sea attacks) affecting global shipping routes.
• **Creditors**: May face increased risk due to the company's reported stockholders' deficit and the 'going concern' qualification in its financial statements.

Next Steps

• Regain and maintain compliance with Nasdaq listing standards, particularly the minimum stockholders' equity requirement.
• File a response to Kukbo's appeal on or before August 6, 2025.
• Attend the Kukbo appeal hearing scheduled for September 2025.
• Continue development for FDA approval of RHB-102 in the U.S.
• Potentially file one or more new registration statements to register resale of additional ADSs if the initial 5,263,157 AMPA ADSs are sold under the equity line of credit.

Key Dates

Recommendation

Keywords

RedHill Biopharma, RDHL, SEC F-1, Equity Line of Credit, ADSs, Nasdaq Compliance, Stockholders Deficit, Biopharmaceutical, GI, Infectious Diseases, Oncology, Talicia, Opaganib, RHB-107, RHB-102, Bekinda, Kukbo Litigation, Hyloris Pharmaceuticals, ATM Program, Capital Raise, Risk Factors, Israel